Diabetic neuropathy is a nerve disorder manifested by different faceted condition affecting up to half of individuals with persistent diabetes. Symptoms associated with this disease such as nerve palsy, painful polyneuropathy, thoracoabdominal neuropathy, autonomic neuropathy, diabetic amyotrophy, mononeuropathy multiplex, caused by motor, sensory, and autonomic nerve dysfunction which affects peripheral nervous system, gastrointestinal, pain receptors, urogenital, and cardiovascular system. In this study, type 2 diabetes was induced with alloxan in albino mice. After induction, drug treatment was initiated on the day 15, with different regimen on different group of mice that is teneligliptin, sitagliptin, combination of teneligliptin, and gabapentin. After investigation on day 21, 28, 35, and 42 found significantly improved glycemic control, paw jumping response, and grip strength (P < 0.001). Mice treated with different regimen on day 21, 28, 35, and 42 were observed significant increase in blood protein (P < 0.001). Alloxan caused marked nerve cell degeneration, teneligliptin and sitagliptin showed tissue regeneration and neutral effect on body weight. In the conclusion, treatment with teneligliptin and teneligliptin combined with gabapentin results an increase in pain sensitivity, grip strength, neural protection, and reverses the alteration of biochemical parameters but neutral effect on body weight in alloxan-induced type 2 diabetic mice.